NYSE
75.05USD
+0.76 (+1.02%)
We have scored 26 news catalysts on Globus Medical, Inc. (GMED) over the past 12 months. The biggest single-day move next to one of them came Nov 7, 2025, when GMED closed +35.9%: “Today's Market Moving Stocks: Affirm Holdings, Expedia, and Globus Medical”. Coverage across the window leans positive (average ticker sentiment +0.83). Most of the impact sits in sector healthcare and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
10.1B
P/E
—
EPS
—
Beta
0.96
52W range
54.15-101.4
Day range
74.37–75.31
Open
74.99
Prev close
74.29
Volume
750.5K
Avg volume
1.6M
Dividend
0.00
IPO
2012-08-03
Analysts publish price targets on GMED, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
6 analyst price targets from $80 to $115
as of 2026-09-10
The market is 23% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Globus Medical, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Globus Medical, Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for GMED: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
The price sits at the very bottom of the published model range, rejecting all four bull cases to trade 23% below the median target, which shows the market firmly assumes the recent 16.7% growth will collapse toward a 3% pace.
What the disagreement turns on
Does the 10% U.S. spine market-share gain represent a durable structural shift that keeps overall revenue growth in the mid-teens, and the available unit volume data can actually measure this.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
